Dave Ricks, CEO of Eli Lilly, shares insights from the J.P. Morgan Healthcare Conference. He discusses the challenges of pricing and accessing GLP-1 obesity medications, despite high demand. Ricks delves into the implications of the Inflation Reduction Act on drug pricing and regulatory hurdles. He emphasizes the importance of business relationships with the incoming Trump administration and aims for Eli Lilly to reach a trillion-dollar valuation in healthcare. The conversation also touches on significant biotech M&A activities and the evolving landscape of drug development.

Dave Ricks, CEO of Eli Lilly, dives into the company's bold $2.5 billion acquisition of Scorpion Therapeutics' breast cancer program, signaling a major commitment to oncology. He discusses the anticipated approval of Lilly's innovative oral weight-loss pill in early 2026 and its potential advantages over current treatments. Ricks also addresses the critical issue of drug pricing, exploring strategies for making new medications accessible while ensuring they deliver value and effective outcomes.

In this discussion, Dave Ricks, CEO of Eli Lilly, shares insights on the company's groundbreaking weight-loss drugs, like Zepbound and terzepatide. He elaborates on their potential in treating addictive behaviors and combating the rising global obesity crisis. Ricks highlights the need for accessible treatments and the complexities of drug manufacturing. He also reflects on his career journey and the transformative impact these medications can have on patients' lives, emphasizing the importance of sustainable health changes.